Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $166 from $162 and keeps a Neutral rating on the shares after updating the firm’s company model following Q4 results that largely met or slightly topped analyst and investor expectations. Looking forward, the firm says it will be monitoring pipeline readouts and execution in oncology, immunology, and neuroscience to see if J&J can sustain its mid-single-digit growth aspirations while waiting to see how J&J navigates it near-term headwinds and delivers on its Innovative Medicine pipeline.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Opening Day: Infinity Natural Resources valued at $1.3B in market debut
- European Commission authorizes Vocabria + Rekambys for HIV treatment
- Artiva expands Board with appointment of Dan Baker, M.D
- Johnson & Johnson’s Earnings Call: Growth Amid Challenges
- Johnson & Johnson price target raised to $166 from $159 at Barclays